Roxanna Haghighat1, Elona Toska2,3, Nontuthuzelo Bungane4, Lucie Cluver5,6. 1. Department of Social Policy and Intervention, University of Oxford, 32 Wellington Square, Oxford, OX1 3DW, UK. roxanna.haghighat@spi.ox.ac.uk. 2. Centre for Social Science Research, University of Cape Town, Cape Town, South Africa. 3. Department of Sociology, University of Cape Town, Cape Town, South Africa. 4. Department of Nursing Science, Faculty of Health Sciences, University of Fort Hare, Alice, South Africa. 5. Department of Social Policy and Intervention, University of Oxford, 32 Wellington Square, Oxford, OX1 3DW, UK. 6. Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.
Abstract
BACKGROUND: Little evidence exists to comprehensively estimate adolescent viral suppression after initiation on antiretroviral therapy in sub-Saharan Africa. This study examines adolescent progression along the HIV care cascade to viral suppression for adolescents initiated on antiretroviral therapy in South Africa. METHODS: All adolescents ever initiated on antiretroviral therapy (n=1080) by 2015 in a health district of the Eastern Cape, South Africa, were interviewed in 2014-2015. Clinical records were extracted from 52 healthcare facilities through January 2018 (including records in multiple facilities). Mortality and loss to follow-up rates were corrected for transfers. Predictors of progression through the HIV care cascade were tested using sequential multivariable logistic regressions. Predicted probabilities for the effects of significant predictors were estimated by sex and mode of infection. RESULTS: Corrected mortality and loss to follow-up rates were 3.3 and 16.9%, respectively. Among adolescents with clinical records, 92.3% had ≥1 viral load, but only 51.1% of viral loads were from the past 12 months. Adolescents on ART for ≥2 years (AOR 3.42 [95%CI 2.14-5.47], p< 0.001) and who experienced decentralised care (AOR 1.39 [95%CI 1.06-1.83], p=0.018) were more likely to have a recent viral load. The average effect of decentralised care on recent viral load was greater for female (AOR 2.39 [95%CI 1.29-4.43], p=0.006) and sexually infected adolescents (AOR 3.48 [95%CI 1.04-11.65], p=0.043). Of the total cohort, 47.5% were recorded as fully virally suppressed at most recent test. Only 23.2% were recorded as fully virally suppressed within the past 12 months. Younger adolescents (AOR 1.39 [95%CI 1.06-1.82], p=0.017) and those on ART for ≥2 years (AOR 1.70 [95%CI 1.12-2.58], p=0.013) were more likely to be fully viral suppressed. CONCLUSIONS: Viral load recording and viral suppression rates remain low for ART-initiated adolescents in South Africa. Improved outcomes for this population require stronger engagement in care and viral load monitoring.
BACKGROUND: Little evidence exists to comprehensively estimate adolescent viral suppression after initiation on antiretroviral therapy in sub-Saharan Africa. This study examines adolescent progression along the HIV care cascade to viral suppression for adolescents initiated on antiretroviral therapy in South Africa. METHODS: All adolescents ever initiated on antiretroviral therapy (n=1080) by 2015 in a health district of the Eastern Cape, South Africa, were interviewed in 2014-2015. Clinical records were extracted from 52 healthcare facilities through January 2018 (including records in multiple facilities). Mortality and loss to follow-up rates were corrected for transfers. Predictors of progression through the HIV care cascade were tested using sequential multivariable logistic regressions. Predicted probabilities for the effects of significant predictors were estimated by sex and mode of infection. RESULTS: Corrected mortality and loss to follow-up rates were 3.3 and 16.9%, respectively. Among adolescents with clinical records, 92.3% had ≥1 viral load, but only 51.1% of viral loads were from the past 12 months. Adolescents on ART for ≥2 years (AOR 3.42 [95%CI 2.14-5.47], p< 0.001) and who experienced decentralised care (AOR 1.39 [95%CI 1.06-1.83], p=0.018) were more likely to have a recent viral load. The average effect of decentralised care on recent viral load was greater for female (AOR 2.39 [95%CI 1.29-4.43], p=0.006) and sexually infected adolescents (AOR 3.48 [95%CI 1.04-11.65], p=0.043). Of the total cohort, 47.5% were recorded as fully virally suppressed at most recent test. Only 23.2% were recorded as fully virally suppressed within the past 12 months. Younger adolescents (AOR 1.39 [95%CI 1.06-1.82], p=0.017) and those on ART for ≥2 years (AOR 1.70 [95%CI 1.12-2.58], p=0.013) were more likely to be fully viral suppressed. CONCLUSIONS: Viral load recording and viral suppression rates remain low for ART-initiated adolescents in South Africa. Improved outcomes for this population require stronger engagement in care and viral load monitoring.
Entities:
Keywords:
Adolescent; Antiretroviral therapy; Care cascade; Continuum of care; HIV; South Africa
Authors: Amy L Slogrove; Michael Schomaker; Mary-Ann Davies; Paige Williams; Suna Balkan; Jihane Ben-Farhat; Nancy Calles; Kulkanya Chokephaibulkit; Charlotte Duff; Tanoh François Eboua; Adeodata Kekitiinwa-Rukyalekere; Nicola Maxwell; Jorge Pinto; George Seage; Chloe A Teasdale; Sebastian Wanless; Josiane Warszawski; Kara Wools-Kaloustian; Marcel Yotebieng; Venessa Timmerman; Intira J Collins; Ruth Goodall; Colette Smith; Kunjal Patel; Mary Paul; Diana Gibb; Rachel Vreeman; Elaine J Abrams; Rohan Hazra; Russell Van Dyke; Linda-Gail Bekker; Lynne Mofenson; Marissa Vicari; Shaffiq Essajee; Martina Penazzato; Gabriel Anabwani; Edith Q Mohapi; Peter N Kazembe; Makhosazana Hlatshwayo; Mwita Lumumba; Tessa Goetghebuer; Claire Thorne; Luisa Galli; Annemarie van Rossum; Carlo Giaquinto; Magdalena Marczynska; Laura Marques; Filipa Prata; Luminita Ene; Liubov Okhonskaia; Pablo Rojo; Claudia Fortuny; Lars Naver; Christoph Rudin; Sophie Le Coeur; Alla Volokha; Vanessa Rouzier; Regina Succi; Annette Sohn; Azar Kariminia; Andrew Edmonds; Patricia Lelo; Samuel Ayaya; Patricia Ongwen; Laura F Jefferys; Sam Phiri; Mwangelwa Mubiana-Mbewe; Shobna Sawry; Lorna Renner; Mariam Sylla; Mark J Abzug; Myron Levin; James Oleske; Miriam Chernoff; Shirley Traite; Murli Purswani; Ellen G Chadwick; Ali Judd; Valériane Leroy Journal: PLoS Med Date: 2018-03-01 Impact factor: 11.069
Authors: Mhairi Maskew; Jacob Bor; William MacLeod; Sergio Carmona; Gayle G Sherman; Matthew P Fox Journal: Lancet HIV Date: 2019-10-01 Impact factor: 16.070
Authors: Olurotimi A Adejumo; Kathleen M Malee; Patrick Ryscavage; Scott J Hunter; Babafemi O Taiwo Journal: J Int AIDS Soc Date: 2015-09-16 Impact factor: 5.396
Authors: Gillian Dougherty; Steve Akoth; Mark Hawken; Isaac Leting; Redempta Mutei; Catherine Ngugi; Doris Naitore; Fatima Tsiouris; Anne Wakoli; Lauren Walker; Miriam Rabkin Journal: BMJ Open Qual Date: 2022-08